{'fraction_non_alphanumeric': 0.031704095112285335, 'fraction_numerical': 0.01453104359313078, 'mean_word_length': 5.478632478632479, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
c‐myc over‐expression in human primary ovarian tumours: Its relevance to tumour progression

Expression of the c‐myc gene was analyzed in 56 human primary ovarian cancer tissues, including 51 common epithelial and 5 non‐epithelial tumours to determine molecular events in the carcinogenic process in ovaries. Over‐expression of the c‐myc gene was found in 37.3% of all ovarian tumour tissues, and in 63.5% of serous adenocarcinoma tissues. Significant over‐expression of the c‐myc gene at Stage III compared with other stages, and one remarkable case of over‐expression in a serous tumour of low malignant potential suggest that c‐myc expression is temporarily activated at some stage(s) during tumorigenesis of ovarian cancer, especially of serous tumours.